Friedreich Ataxia - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Friedreich Ataxia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Friedreich Ataxia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Featured News & Press Releases (2017-2018)Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich’s Ataxia Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich’s Ataxia
Companies FeaturedAdverum Biotechnologies Inc Agios Pharmaceuticals Inc BioElectron Technology Corp BioMarin Pharmaceutical Inc Biovista Inc Horizon Pharma Plc Ixchel Pharma LLC Pfizer Inc PTC Therapeutics Inc Reata Pharmaceuticals Inc STATegics Inc Takeda Pharmaceutical Co Ltd Voyager Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/47qdmb/friedreich_ataxia?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005519/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/17/2018 11:50 AM/DISC: 09/17/2018 11:50 AM